<DOC>
	<DOC>NCT00634946</DOC>
	<brief_summary>The purpose of this study is to determine whether SI-6603 is effective in the treatment of lumbar disc herniation.</brief_summary>
	<brief_title>SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation</brief_title>
	<detailed_description />
	<mesh_term>Hernia</mesh_term>
	<mesh_term>Intervertebral Disc Displacement</mesh_term>
	<criteria>Patients with lumbar disc herniation (L4L5 or L5S1) as assessed by MRI and clinical symptoms corresponding to position of the impaired nerve root Patients assessed as positive in the SLR test Patients with sciatica in either lower leg Patients with no improvement from pharmacotherapy or concomitant treatment with drug and nerve block Patients who have 2 or more lumbar disc herniations as assessed by MRI Patients with "extrusiontype" or "sequestrationtype" herniation in whom a rupture into the posterior longitudinal ligament is identified by MRI Patients who have received nerve block within 3 weeks before screening Patients who have undergone lumbar operation, chemonucleolysis, or percutaneous nucleotomy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Chemonucleolysis</keyword>
	<keyword>Lumbar Vertebrae</keyword>
	<keyword>Hernia</keyword>
</DOC>